Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
KY02111 (KY 02111; KY-02111) is a potent and selective inhibitor of the Wnt signaling pathway with important biological activity. It promotes the differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, and may also act downstream of APC and GSK3β. When tested with IMR90-1 hiPSCs transfected with TCF receptor plasmids, KY 02111 (1 μM) significantly reduced luciferase activities in a dose-dependent manner by inhibiting canonical WNT signaling pathway. In cardiac colonies on the day 30, KY 02111 showed that nearly 73%-85% of IMR90-1 hiPSCs expressed the cardiac markers.
ln Vitro |
KY02111 inhibits WNT signaling in hPSCs to enhance differentiation[1]. Cardiomyocytes expressed αMHC, NKH2.5, and HCN4 are induced by KY02111[1]. In HEK293 and IMR90-1 cells, KY02111 (1–10 μM; 12 hours, 24 hours) decreases WNT signaling in a dose-dependent manner[1]. Treatment of KY02111 with WNT signaling modulators results in robust cardiac differentiation of hPSCs in a defined media free of xeno-agents and recombinant hormones and cytokines, including insulin, BMP4, and Activin A[1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Minami I, et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012 Nov 29;2(5):1448-60.
|
Molecular Formula |
C18H17CLN2O3S
|
|
---|---|---|
Molecular Weight |
376.86
|
|
CAS # |
1118807-13-8
|
|
SMILES |
ClC1C([H])=C([H])C2=C(C=1[H])SC(=N2)N([H])C(C([H])([H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])OC([H])([H])[H])=O
|
|
InChi Key |
LXFKEVQQSKQXPR-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C18H17ClN2O3S/c1-23-14-7-3-11(9-15(14)24-2)4-8-17(22)21-18-20-13-6-5-12(19)10-16(13)25-18/h3,5-7,9-10H,4,8H2,1-2H3,(H,20,21,22)
|
|
Chemical Name |
N-(6-Chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6535 mL | 13.2675 mL | 26.5351 mL | |
5 mM | 0.5307 mL | 2.6535 mL | 5.3070 mL | |
10 mM | 0.2654 mL | 1.3268 mL | 2.6535 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.